EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan.
| Published in: | Cancer Letters Vol. 654 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Published: |
Elsevier B.V.
Aug2026
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=194226326&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 194226326 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 03043835 3J8 jtl: Cancer Letters issn: 03043835 maglogo: N pubinfo: dt: Aug2026 vid: 654 pid: 1004 pub: Elsevier B.V. artinfo: ui: 194226326 10.1016/j.canlet.2026.218607 194226326 ppct: 1 formats: tig: atl: EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan. aug: au: Harmych, Sarah J. Joshi, Neeraj Tanaka, Hidenori Bogatcheva, Galina Ramirez, Marisol A. Graves-Deal, Ramona Tydings, Claiborne W. Elia, Marina T. Mueller, Hunter R Lischwe Silvestri, Isabella M. Ti Ning, Khaw Wahoski, Claudia C. Sievers, Chelsie K. Higginbotham, James N. Irudayam, Maria Johnson Revetta, Frank L. Zhao, Zhiguo Franklin, Jeffrey L. Yilma, Binyam O'Grady, Tina M. affil: Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37232, USA sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|